The activating STAT5B N642H mutation is a common abnormality in pediatric T-cell acute lymphoblastic leukemia and confers a higher risk of relapse.
作者信息
Bandapalli Obul R, Schuessele Stephanie, Kunz Joachim B, Rausch Tobias, Stütz Adrian M, Tal Noa, Geron Ifat, Gershman Nava, Izraeli Shai, Eilers Juliane, Vaezipour Nina, Kirschner-Schwabe Renate, Hof Jana, von Stackelberg Arend, Schrappe Martin, Stanulla Martin, Zimmermann Martin, Koehler Rolf, Avigad Smadar, Handgretinger Rupert, Frismantas Viktoras, Bourquin Jean Pierre, Bornhauser Beat, Korbel Jan O, Muckenthaler Martina U, Kulozik Andreas E
机构信息
Department of Pediatric Oncology, Hematology and Immunology, Children's Hospital, University of Heidelberg, Germany Molecular Medicine Partnership Unit, EMBL-University of Heidelberg, Germany.
European Molecular Biology Laboratory (EMBL), Genome Biology Unit, Heidelberg, Germany.
出版信息
Haematologica. 2014 Oct;99(10):e188-92. doi: 10.3324/haematol.2014.104992. Epub 2014 Jun 27.
Abstract
摘要
相似文献
1
The activating STAT5B N642H mutation is a common abnormality in pediatric T-cell acute lymphoblastic leukemia and confers a higher risk of relapse.激活型STAT5B N642H突变是儿童T细胞急性淋巴细胞白血病中的常见异常，会增加复发风险。
Haematologica. 2014 Oct;99(10):e188-92. doi: 10.3324/haematol.2014.104992. Epub 2014 Jun 27.
2
Rare occurrence of a STAT5B N642H mutation in adult T-cell acute lymphoblastic leukemia.成人T细胞急性淋巴细胞白血病中罕见的STAT5B N642H突变发生情况。
Cancer Genet. 2015 Jan-Feb;208(1-2):52-3. doi: 10.1016/j.cancergen.2014.12.001. Epub 2014 Dec 19.
3
Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia.新型激活型STAT5B突变作为T细胞急性淋巴细胞白血病的潜在驱动因素
Leukemia. 2014 Aug;28(8):1738-42. doi: 10.1038/leu.2014.89. Epub 2014 Feb 27.
4
Unveiling myeloid transformation: T-LGLL with eosinophilia masking myeloid-associated STAT5B mutation culminating in AML.揭示髓系转化：伴有嗜酸性粒细胞增多的T-LGLL掩盖了髓系相关的STAT5B突变，最终发展为急性髓系白血病。
Br J Haematol. 2024 Jun;204(6):2487-2491. doi: 10.1111/bjh.19421. Epub 2024 Mar 20.
5
Structural and functional consequences of the STAT5B driver mutation.STAT5B 驱动突变的结构和功能后果。
Nat Commun. 2019 Jun 7;10(1):2517. doi: 10.1038/s41467-019-10422-7.
6
Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophilia.伴有嗜酸性粒细胞增多的髓系肿瘤中复发性激活 STAT5B N642H 突变。
Leukemia. 2019 Feb;33(2):415-425. doi: 10.1038/s41375-018-0342-3. Epub 2018 Dec 20.
7
Targeting STAT5B in T-cell acute lymphoblastic leukemia.靶向T细胞急性淋巴细胞白血病中的信号转导和转录激活因子5B（STAT5B）
Blood. 2023 Jul 20;142(3):215-217. doi: 10.1182/blood.2023020639.
8
Single-cell profiling of pediatric T-cell acute lymphoblastic leukemia: Impact of PTEN exon 7 mutation on PI3K/Akt and JAK-STAT signaling pathways.儿童 T 细胞急性淋巴细胞白血病的单细胞分析：PTEN 外显子 7 突变对 PI3K/Akt 和 JAK-STAT 信号通路的影响。
Cytometry B Clin Cytom. 2020 Nov;98(6):491-503. doi: 10.1002/cyto.b.21882. Epub 2020 Jun 1.
9
Prognostic value of Oncogenetic mutations in pediatric T Acute Lymphoblastic Leukemia: a comparison of UKALL2003 and FRALLE2000T protocols.小儿T急性淋巴细胞白血病中肿瘤基因突变的预后价值：UKALL2003与FRALLE2000T方案的比较
Leukemia. 2022 Jan;36(1):263-266. doi: 10.1038/s41375-021-01334-x. Epub 2021 Jun 28.
10
STAT5 activation promotes progression and chemotherapy resistance in early T-cell precursor acute lymphoblastic leukemia.STAT5 激活促进早期 T 细胞前体急性淋巴细胞白血病的进展和化疗耐药性。
Blood. 2023 Jul 20;142(3):274-289. doi: 10.1182/blood.2022016322.
引用本文的文献
1
The structural influence of the oncogenic driver mutation N642H in the STAT5B SH2 domain.致癌驱动突变N642H对STAT5B SH2结构域的结构影响。
Protein Sci. 2025 Jan;34(1):e70022. doi: 10.1002/pro.70022.
2
Perinatal thymic-derived CD8αβ-expressing γδ T cells are innate IFN-γ producers that expand in IL-7R-STAT5B-driven neoplasms.围生期胸腺来源的 CD8αβ 表达 γδ T 细胞是先天 IFN-γ 产生细胞，在 IL-7R-STAT5B 驱动的肿瘤中扩增。
Nat Immunol. 2024 Jul;25(7):1207-1217. doi: 10.1038/s41590-024-01855-4. Epub 2024 May 27.
3
Hyperactive STAT5 hijacks T cell receptor signaling and drives immature T cell acute lymphoblastic leukemia.过度活跃的信号转导和转录激活因子5（STAT5）劫持T细胞受体信号传导并驱动未成熟T细胞急性淋巴细胞白血病。
J Clin Invest. 2024 Apr 15;134(8):e168536. doi: 10.1172/JCI168536.
4
A lineage-specific STAT5BN642H mouse model to study NK-cell leukemia.一种用于研究自然杀伤细胞白血病的谱系特异性STAT5B N642H小鼠模型。
Blood. 2024 Jun 13;143(24):2474-2489. doi: 10.1182/blood.2023022655.
5
JAK/STAT in leukemia: a clinical update.白血病中的JAK/STAT：临床最新进展
Mol Cancer. 2024 Jan 26;23(1):25. doi: 10.1186/s12943-023-01929-1.
6
Targeting of STAT5 using the small molecule topotecan hydrochloride suppresses acute myeloid leukemia progression.利用小分子拓扑替康盐酸盐靶向 STAT5 抑制急性髓系白血病进展。
Oncol Rep. 2023 Dec;50(6). doi: 10.3892/or.2023.8645. Epub 2023 Oct 13.
7
Genetic Variants Leading to Urticaria and Angioedema and Associated Biomarkers.导致荨麻疹和血管性水肿的遗传变异及其相关生物标志物。
J Allergy Clin Immunol Pract. 2023 Aug;11(8):2286-2301. doi: 10.1016/j.jaip.2023.05.031. Epub 2023 May 30.
8
JAK1 Pseudokinase V666G Mutant Dominantly Impairs JAK3 Phosphorylation and IL-2 Signaling.JAK1 假激酶 V666G 突变体显性抑制 JAK3 磷酸化和 IL-2 信号通路。
Int J Mol Sci. 2023 Apr 6;24(7):6805. doi: 10.3390/ijms24076805.
9
Pentacyclic Triterpenoids-Based Ionic Compounds: Synthesis, Study of Structure-Antitumor Activity Relationship, Effects on Mitochondria and Activation of Signaling Pathways of Proliferation, Genome Reparation and Early Apoptosis.基于五环三萜类化合物的离子化合物：合成、结构-抗肿瘤活性关系研究、对线粒体的影响以及增殖、基因组修复和早期凋亡信号通路的激活
Cancers (Basel). 2023 Jan 26;15(3):756. doi: 10.3390/cancers15030756.
10
Genomic Mutations of the STAT5 Transcription Factor Are Associated with Human Cancer and Immune Diseases.STAT5 转录因子的基因组突变与人类癌症和免疫性疾病相关。
Int J Mol Sci. 2022 Sep 25;23(19):11297. doi: 10.3390/ijms231911297.
本文引用的文献
1
Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia.新型激活型STAT5B突变作为T细胞急性淋巴细胞白血病的潜在驱动因素
Leukemia. 2014 Aug;28(8):1738-42. doi: 10.1038/leu.2014.89. Epub 2014 Feb 27.
2
Comprehensive analysis of transcriptome variation uncovers known and novel driver events in T-cell acute lymphoblastic leukemia.全面分析转录组变异揭示 T 细胞急性淋巴细胞白血病中的已知和新的驱动事件。
PLoS Genet. 2013;9(12):e1003997. doi: 10.1371/journal.pgen.1003997. Epub 2013 Dec 19.
3
Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia.大颗粒淋巴细胞白血病中体细胞 STAT5b 突变的发现。
Blood. 2013 May 30;121(22):4541-50. doi: 10.1182/blood-2012-12-474577. Epub 2013 Apr 17.
4
NOTCH1 activation clinically antagonizes the unfavorable effect of PTEN inactivation in BFM-treated children with precursor T-cell acute lymphoblastic leukemia.NOTCH1 激活在 BFM 治疗的前体 T 细胞急性淋巴细胞白血病患儿中，临床上拮抗了 PTEN 失活的不利影响。
Haematologica. 2013 Jun;98(6):928-36. doi: 10.3324/haematol.2012.073585. Epub 2013 Jan 24.
5
Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia.外显子组测序鉴定出 T 细胞急性淋巴细胞白血病中 CNOT3 基因和核糖体基因 RPL5、RPL10 的突变。
Nat Genet. 2013 Feb;45(2):186-90. doi: 10.1038/ng.2508. Epub 2012 Dec 23.
6
Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia.致癌性 IL7R 获得性功能突变导致儿童 T 细胞急性淋巴细胞白血病。
Nat Genet. 2011 Sep 4;43(10):932-9. doi: 10.1038/ng.924.
7
Gain-of-function mutations in interleukin-7 receptor-α (IL7R) in childhood acute lymphoblastic leukemias.儿童急性淋巴细胞白血病中白细胞介素-7 受体-α（IL7R）的功能获得性突变。
J Exp Med. 2011 May 9;208(5):901-8. doi: 10.1084/jem.20110580. Epub 2011 May 2.
8
The favorable effect of activating NOTCH1 receptor mutations on long-term outcome in T-ALL patients treated on the ALL-BFM 2000 protocol can be separated from FBXW7 loss of function.NOTCH1 受体突变对接受 ALL-BFM 2000 方案治疗的 T-ALL 患者长期预后的有利影响，可以与 FBXW7 功能丧失相分离。
Leukemia. 2010 Dec;24(12):2005-13. doi: 10.1038/leu.2010.203. Epub 2010 Oct 14.
9
Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia.T 细胞急性淋巴细胞白血病中蛋白酪氨酸磷酸酶基因 PTPN2 的缺失。
Nat Genet. 2010 Jun;42(6):530-5. doi: 10.1038/ng.587. Epub 2010 May 16.
10
PHF6 mutations in T-cell acute lymphoblastic leukemia.PHF6 突变与 T 细胞急性淋巴细胞白血病。
Nat Genet. 2010 Apr;42(4):338-42. doi: 10.1038/ng.542. Epub 2010 Mar 14.
Zotero 插件